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ABSTRACT 
The colon is being extensively investigated as a drug delivery site. Colonic drug delivery is a relatively recent approach for the 
treatment of diseases like ulcerative colitis, Crohn’s disease, and irritable bowel syndrome. To achieve successful colon targeted 
drug delivery, a drug needs to be protected from degradation, release and /or absorption in upper portion of GI tract and then ensure 
abrupt or controlled release in proximal colon. The purpose of this research is to develop and evaluate the polysaccharide based 
compression coated tablets of Tegaserod maleate for the treatment of irritable bowel syndrome. Core tablets of Tegaserod maleate 
were compression coated with various proportions of Galactosol, xanthan gum and chitosan. This work aimed to prepare 
compression coated tablets by direct compression method using single polymer and combination of polymers. And to evaluate 
prepared tablets parameters like hardness, friability, thickness, diameter, weight variation, drug content, swelling index, in vitro drug 
release. 
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INTRODUTION 
Tegaserod maleate (TM) is the first selective 
5‐hydroxytryptamine type‐4 (5‐HT4) receptor partial 
agonist used for the treatment of constipation 
predominant irritable bowel syndrome (IBS), a complex 
gastrointestinal disorder characterized by a combination 
of abdominal pain, is comfort, diarrhea, and/or 
constipation. TM is insoluble in water and has pH 
dependent solubility. Below pH 3, TM is rapidly 
degraded through hydrolytic breakdown. TM is readily 
absorbed following oral administration under fasted 
condition, and the peak plasma concentration occurs 
after 1.0‐1.3 hr. Absolute bioavailability is about 10 %, 
and terminal elimination half‐life is close to 11 hr. To 
improve the oral bioavailability and prevent rapid 
hydrolysis of TM in gastric milieu, a dosage form 
containing TM is coated with polysaccharides based 
polymers. Rationale for development of a 
polysaccharides based delivery system for colon is the 
presence of large amount of polysaccharidases in human 
colon as the colon in inhabitated by a large number and 
variety of bacteria which secrete enzymes viz β-
Dglucosidase, β-D-galactosidase, amylase, pectinase, 
xylanase. Various major approaches utilizing 
polysaccharides for colon-specific delivery is 
fermentable coating of the drug core, embedding of the 
drug in biodegradable matrix and formulation of drug 
saccharide conjugate (Prodrugs). A large number of 
polysaccharides have already been studied for their 
potential as colon-specific drug carrier systems, such as 
chitosan, pectin, chondroitin sulphate, guar gum, 
xanthan gum, khaya gum, inulin, amylose and locust 
bean gum.
1, 2, 3, 4, 5
 
This work aimed to prepare compression coated tablets 
by direct compression method using single polymer and 
combination of polymers. And to evaluate prepared 
tablets parameters like hardness, friability, thickness, 
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diameter, weight variation, drug content, swelling index, 
in vitro drug release. 
MATERIALS AND METHODS 
Materials 
The drug Tegaserod maleate was received as a gift 
sample from Hetero drugs, Hyderabad. Galactosol was 
purchased from SD fine chemicals, Mumbai.  Chitosan 
and Xanthan gum were purchased from Himedia 
laboratories Ltd, Mumbai. Magnesium Stearate and Talc 
were obtained from SD Fine chemicals Mumbai. All the 
other chemicals used were of high analytical grade. 
Methods 
Preparation of tablets:  
Preparation of fast disintegrating core tablets: 
The core tablets of tegaserod maleate were prepared by 
direct compression technique using the composition 
given in Table 1. Tegaserod maleate, sodium starch 
glycolate, micro crystalline cellulose, magnesium 
stearate and talc were passed through sieve no #80 (179 
µm), weighed and thoroughly mixed in a polybags to 
ensure complete mixing. The mixture was compressed 
into tablet on a single station tablet punching machine 
using 9.5 mm round, flat-faced and plain punches.
6, 7, 8
 
Table 1: Composition of core tablet 
 
Preparation of compression coated tablets  
The composition of compression coating material is 
shown in Table 2. All the ingredients of each coat 
formulation were weighed accurately and mixed in a 
polybag. 150 mg of coating mixture was placed in the 
die cavity of single station tablet punching machine, the 
core tablet was placed on it at centre, remaining 150 mg 
of coating mixture was carefully transferred to the die 
cavity and tablets were compressed using 12.6 mm flat 
punches. The total weight of the compression coated 
tablet was about 400 mg (100+300 mg).
 6-8 
 
Table 2: Composition of compression coated tablets 
 
Evaluation of tablets:  
A. Physico-chemical evaluation of compression 
coated tablets:  
The prepared tablets were evaluated for diameter, 
thickness, hardness, friability, weight variation and drug 
content. 
(a) Thickness and Diameter: The thickness and 
diameter of the tablets was determined by using dial 
thickness apparatus and vernier calipers respectively. 
Five tablets from each formulation were used and 
average values were noted.
8,9  
(b) Hardness: Tablet hardness of all the formulations 
was determined by using Monsanto hardness tester. Five 
tablets from each formulation were used and average 
values were recorded.
9,10 
(c) Friability: Both core and compression coated tablets 
from all formulations were subjected for friability test 
using friabilator. Ten tablets were weighed and placed 
inside the Roche friabilator. The instrument was 
operated for 4 mins at 25rpm. The resulting tablets after 
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100 falls from a height of six inches were collected; 
weighed and percentage loss was calculated using 
following equations.
10-12 
 
(d) Weight variation test: The weight variation study 
of the prepared formulations was performed as per the 
standard procedure following Indian pharmacopoeia. 
The mean and standard deviation of each batch of tablets 
were tabulated.
11-12 
(e) Determination of drug content: One tablet from 
each formulations of compression coated and the core 
tablets were powdered and transferred in to 100 ml 
volumetric flask. Initially 50 ml of phosphate buffer (pH 
6.8) was added and allowed to rotate in a rotary shaker 
for 24 h; the final volume was made up with phosphate 
buffer (pH 6.8). The solution was filtered and amount of 
secnidazole present in the solution was estimated by 
using UV- spectrophotometer (UV 1601, Shimadzu, 
Japan) at 315 nm against a suitable blank.
10-12
 
B. Swelling index:  
One tablet from each formulation was randomly 
selected, weighed individually (WO) and placed 
separately in a wire basket which was placed in a 100 ml 
beaker containing 0.1 N HCl for first 2 h and pH 6.8 for 
remaining 22 h. At the end of 2, 4, 6, 8 and 24 h the 
tablets were removed from wire basket and excess water 
was removed using filter paper. The swollen tablets were 
reweighed (Wt) and swelling index of each tablet was 
calculated using the below equation.
12-14 
 
C. Preparation of 2% rat caecal content:  
Male wistar rats weighing 150-200 gm maintaine to 
rotate in a rotary shaker for 24 h; the final volume was 
made up with phosphate buffer (pH 6.8). The solution 
was filtered and amount of secnidazole present in the 
solution was estimated by using UV- spectrophotometer 
(UV 1601, Shimadzu, Japan) at 315 nm against a 
suitable blank.
13-15
 In order to assess the susceptibility of 
Galactosol and xanthan gum, being ac upon by colonic 
bacteria, drug release studies were also carried out in 
presence of caecal content because of the similarity with 
human intestinal flora. In vitro d release studies in the 
presence of rat caecal contents were same as mentioned 
abo except that rat caecal content (2% w/v) was added 
only to phosphate buffer (pH 7 to simulate colonic 
condition.
11-15 
 
D. Release kinetics: 
In vitro release data were fit to zero order, first order and 
higuchi equations to analyze the kinetics of drug release 
from the tablets. Further, in vitro release results were fit 
to the following Koresmeyer-Peppas equation, to 
analyse drug release mechanism.  
Mt/Mα = Kt Where Mt/Mα is the fraction of drug 
released at time t, K is kinetic constant and 
‘n’ is release exponent that characterize the drug 
transport.
13-15
 
RESULTS AND DISUSSION 
In the present work colon targeted compression coated 
tablets were prepared by direct compression technique 
using Tegaserod maleate as a model drug for treatment 
of diseases like ulcerative colitis, Crohn’s disease, and 
irritable bowel syndrome. The compression coated 
tablets of Tegaserod maleate were prepared using natural 
polymers 
like Galactosol, xanthan gum and chitosan. Further, it 
was aimed to identify the most suitable polysaccharide 
either alone or in combinations for colonic delivery of 
Tegaserod maleate based on microbial degradation. 
Hence attempts were made to formulate the compression 
coated tablets using Galactosol, xanthan gum, chitosan, 
either alone or in combination. The formulations were 
evaluated for physical parameters like diameter, 
thickness, hardness, friability and drug content. 
Evaluations of other parameters like swelling index, in 
vitro drug release, release kinetics and stability were also 
conducted. 
Evaluation of tablets 
Physico-chemical characterization of core tablet and 
compression coated tablets 
a) Thickness: The thickness of core tablets were found 
to be 1.96±0.05 mm and for compression coated tablets 
of all the batches of formulation prepared ranges in 
between 2.54±0.05 mm and 2.71±0.09 mm. 
b) Diameter: The diameter of core tablets was found 
9.67±0.02 mm and for compression coated tablets of 
each formulation was ranged between 13.13±0.05 mm 
and 13.15±0.08 mm. 
c) Hardness: The hardness for compression coated 
tablets of each formulation was found in the range of 
5.86±0.05 and 6.13±0.06 kg/cm
2
, this ensures good 
handling characteristics of all batches. The hardness of 
core tablets of Tegaserod maleate was found to be 
3.1±0.15 kg/cm
2
. 
d) Friability: The values of friability test were depicted 
in table 21. The percentage friability of all formulations 
was found in the range of 0.91±0.13 to 0.98±0.05%; 
indicating that the friability is within the acceptable 
limits and tablets were mechanically stable. In case of 
core tablets the percentage friability was more and it was 
found to be 2.96±0.15%, because core tablets are 
compressed at lower compressional force. 
e) Weight variation: The percentage weight variations 
for all formulations were depicted in table 3. The results 
of weight variation of tablets for all compression coated 
tablet formulations was found in the range of 
398.19±0.05 to 399.05±0.05 mg and in case of core 
tablets it was found to be 98.81±0.12 mg; indicating that 
the weight variation is within the pharmacopoeial limits. 
f) Drug content: The percentage drug content both for 
core tablets and compression coated tablets of all 
formulations was found in the range of 98.95±0.15 to 
99.62±0.25%, which was well within acceptable limits 
of official standards.  
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Table 3: Physico-chemical parameters of prepared tablets 
Formulation  Thickness 
(mm) 
Diameter 
(mm) 
Hardness 
(kg/cm
2
) 
Weight of 
Tablet (mg) 
Friability (%) Drug 
content (%) 
Core Tablet 1.96±0.05 9.67±0.02 3.1±0.15 98.81±0.12 2.96±0.15 99.51±0.09 
F1 2.71±0.09 13.14±0.05 5.86±0.05 398.71±0.05 0.95±0.17 99.15±0.16 
F2 2.63±0.03 13.15±0.03 6.12±0.09 399.11±0.09 0.91±0.13 99.23±0.21 
F3 2.66±0.06 13.15±0.04 5.95±0.06 398.22±0.10 0.93±0.09 99.61±0.27 
F4 2.67±0.05 13.14±0.04 6.02±0.13 398.19±0.05 0.94±0.08 98.95±0.15 
F5 2.56±0.03 13.15±0.03 5.85±0.15 398.72±0.07 0.89±0.04 99.62±0.25 
F6 2.61±0.08 13.13±0.05 5.94±0.05 398.55±0.08 0.90±0.14 99.12±0.31 
F7 2.68±0.05 13.14±0.05 6.05±0.05 398.56±0.04 0.95±0.14 99.19±0.34 
F8 2.54±0.05 13.15±0.08 6.12±0.08 398.34±0.15 0.94±0.13 99.25±0.15 
F9 2.60±0.02 13.13±0.06 6.11±0.08 398.41±0.17 0.95±0.17 99.45±0.19 
F10 2.69±0.06 13.13±0.08 6.08±0.05 398.43±0.05 0.98±0.05 99.58±0.27 
F11  2.55±0.05 13.14±0.09 6.03±0.11 398.58±0.05 0.88±0.10 99.32±0.25 
F12 2.59±0.09 13.14±0.04 5.79±0.03 398.49±0.11 0.91±0.05 99.35±0.05 
F13 2.61±0.01 13.15±0.03 6.10±0.04 399.05±0.05 0.94±0.05 99.41±0.33 
F14 2.65±0.05 13.14±0.05 6.11±0.03 398.88±0.05 0.91±0.05 99.27±0.51 
F15 2.63±0.03 13.14±0.03 6.13±0.06 398.83±0.18 0.93±0.05 99.52±0.24 
All values are expressed as mean ±SD, n=3 
g) Disintegration test for core tablets: The 
disintegration time was measured for core tablet and it 
was found to disintegrate within 60 sec. 
h) Swelling index: Swelling index elaborated the 
amount of water that is contained within hydrogel at 
equilibrium and is a function of the network structure, 
hydrophilicity and ionization of the functional groups. 
Swelling studies was done for first 2 h in 0.1N HCl (pH 
1.2) and later in phosphate buffer (pH 7.4) up to 24 h, 
simulating transition of tablets in GIT. The swelling 
behavior was dependent upon the polymer or 
combination of the polymers used for coating the core 
tablet. The the plot of swelling index against time (h) is 
depicted in figure 1. 
 
 
Figure 1: Swelling index of compression coated tablet 
 
In vitro release studies:  
Drug release studies were conducted in 0.1N HCl for 
the initial 2 h, followed by phosphate buffer (pH 7.4) 
up to 24 h.  
Mono polymer based coating formulation: 
Among F1, F2 and F3 formulation, F1 and F2 were 
found to have better in vitro release profile required for 
colon targeting. But formulation F2 showed more 
sustaining ability in colonic pH after 8 h than 
formulation F1. 
However formulation F3 containing chitosan released 
almost complete drug in gastric buffer pH 1.2. 
Bipolymer based coating formulation: 
As the chitosan proportion is increased in the coating 
formulation the percentage of drug 
released increased slightly in gastric pH. As the 
Galactosol proportion is increased in the coating 
formulation the percentage of drug released was 
slightly decreased in colonic pH. As the xanthan gum 
proportion is increased in the coating formulation the 
percentage of drug released was slightly decreased in 
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colonic pH. The formulation F9 containing xanthan 
gum is better controlled in colonic condition compared 
to F5 containing guar gum.  
Tripolymer based coating formulation: 
Among the formulation prepared by three polymers, 
the formulation F14 composed of Galactosol, xanthan 
gum and chitosan showed better in vitro release 
profile. The in vitro drug release in presence of rat 
caecal content when compared with in the absence of 
rat caecal content, a significant difference (P < 0.05) 
was observed. Hence in the presence of rat caecal 
matter, drug was released faster from formulations 
compared to dissolution medium without rat caecal 
content. This indicates that the drug release from 
formulations is mainly due to the presence of enzymes 
released by micro-organisms of rat caecal contents. 
 
 
Figure 2:  In vitro release data of Tegaserod maleate 
compression coated tablets 
 
Figure 3:  In vitro release data of Tegaserod maleate 
compression coated tablets 
 
Figure 4:  In vitro release data of Tegaserod 
maleate compression coated tablets 
 
Figure 5: In vitro drug release from compression 
coated tablets of formulation F5, F9 and F14 in 
0.1N HCl (2 h) and in pH 6.8 with rat caecal 
contents 
 Drug release kinetics studies 
All formulations except F3, F4 and F8 showed the 
linearity with respect to zero order as compared to first 
order. 
Formulation F3, F4 and F8 did not showed linearity 
with respect to first order equation. In presence of 2% 
w/v rat caecal content as a dissolution medium, the 
formulation F5, F9 and F14 showed linearity with 
respect to first order equation. Higuchi equation 
regression values for all formulations 
with and without rat caecal contents ranges shows in 
the table 4.  To confirm precisely the domination 
mechanism; the data was plotted according to 
Koresmeyer-Peppas equation. 
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Table 4: Release kinetic data of prepared compression coated tablet of Tegaserod maleate 
Formulations Zero- order (R
2
) First- order (R
2
) First- order (R
2
) Koresmeyer 
peppas model (n) 
F1 0.9773  0.9648 0.8799 1.290 
F2 0.9889  0.9696 0.8990 1.236 
F3 0.6525  0.9655 0.8906 0.492 
F4 0.6448  0.9467 0.8854 0.481 
F5 0.9742  0.9434 0.8928 1.193 
F6 0.9654  0.9536 0.8838 1.227 
F7 0.9632  0.9646 0.8986 1.269 
F8 0.6746  0.9533 0.9004 0.483 
F9 0.9874  0.9336 0.8749 1.202 
F10 0.9829  0.9510 0.8699 1.213 
F11 0.9913  0.9452 0.8563 1.310 
F12 0.9925  0.9390 0.8794 1.149 
F13 0.9853  0.9471 0.9014 1.319 
F14 0.9829  0.9223 0.8793 1.407 
F15 0.9903  0.9399 0.8910 1.272 
 
Table 5: Release kinetic data of formulation F5, F9 and F14 Tegaserod maleate compression coated tablets in 
presence of rat caecal content 
Formulations Zero- order (R
2
) First- order (R
2
) First- order (R
2
) Koresmeyer 
peppas model (n) 
F5 0.8724  0.9703 0.9535 1.412 
F9 0.9214  0.9594 0.9290 1.450 
F14 0.8702  0.9602 0.9243 1.578 
 
 
CONLUSION 
This work aimed to prepare compression coated tablets 
by direct compression method using single polymer and 
combination of polymers. Core tablet of Tegaserod 
maleate was prepared using sodium starch glycolate and 
microcrystalline cellulose Core tablets of Tegaserod 
maleate were compression coated using natural 
polysaccharides like guar gum, xanthan gum and 
chitosan for colon targeting. The prepared tablets were 
evaluated for parameters like hardness, friability, 
thickness, diameter, weight variation, drug content, 
swelling index, in vitro drug release. The results showed 
that in the presence of rat caecal matter, drug was 
released faster from formulations compared to 
dissolution medium without rat caecal content. This 
indicates that the drug release from formulations is 
mainly due to the presence of enzymes released by 
micro-organisms of rat caecal contents. 
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